A conglomerate selling itself off, one crown jewel at a time.

• The structure: seven businesses inside one listed shell — alternatives, a mutual fund, India's largest asset-reconstruction arm, lending, and two insurers — that management is unlocking by listing and selling each one separately.
• The proof: Nuvama is already demerged and partly cashed; the alternatives arm EAAA has filed to IPO; a 15% slice of the mutual fund went to WestBridge — two arms alone now approach the whole $1.23B market cap.
• The catch: net of $700M of holding-company debt, the parts sum to roughly today's price. The gap is leverage, not a giveaway — the upside is a conditional re-rating, not a discount you collect on day one.

Stack the parts, subtract the debt — the price is already on the conservative line.

Value the seven businesses at fair marks and subtract the $700M of holding-company debt that sits ahead of equity, and the conservative sum lands within a cent of the price. The spread to base and bull is not a hidden discount — it is what marking the contested pieces and an EAAA re-rating would add.

One private mark carries three-quarters of the value.

• The weight: EAAA, the alternatives platform, is marked at $900M — about 74% of the entire market cap — off a 4.4% placement that struck 37 times earnings, right on top of listed peer 360 ONE's ~36 times.
• The asterisk: that placement went to 40–45 friendly limited partners capped at $4M a head — a captive book, not a public clearing price — and the fees ride closed-end funds that return capital and must be re-raised yearly, not an annuity.
• The test: the IPO is SEBI-approved and guided for "maybe July, August," but must clear at or above the private mark for the base case to hold. It is the single most important catalyst on the calendar.

Most of the profit rests on a number the company sets itself.

• The dependence: 72% of FY2025 group profit came from Edelweiss ARC, a 60%-owned arm whose earnings rest on its own marks on distressed loans — marks the Reserve Bank of India ordered it to fix in 2024 before lifting the curb that December.
• Mark-driven, not yet cash: the group's single largest revenue line is $360M of fair-value gains, added straight back as a non-cash item in the cash-flow — profit that stays unconfirmed until it is recovered.
• A melting ice cube — that is cashing: fee-paying AUM has halved and the book is in run-off, but recoveries rose to $910M and ~$95M was returned up to the parent. Worth its $315M book, not a cent above.

Two insurers bleed while a 10% funding meter runs.

The holding company funds itself with near-quarterly retail bond sales at up to 10% against a credit book earning close to 1% — a structural bleed that erodes the sum-of-the-parts gap every quarter the unlock slips. The whole case is a race: can FY2027's stake-sale cash arrive before the carry compounds. Net debt has stayed flat despite every prior sale — so far, the meter has been winning.